Abstract
Forty-two patients with stage III melanoma were treated with a combination of CCNU, bleomycin, and vincristine. Seventeen of 35 evaluable patients achieved an objective response (48.5%) including five patients with CRs. The median duration of response was 4 months (range, 1-18 months). The responders had a median survival of 278 days (range, 78-1100 days) and the nonresponders had a median survival of 168 days (range 34-619 days). The toxicity off the combination was within an acceptable range with no toxic deaths.
Publication types
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Adolescent
-
Adult
-
Aged
-
Bleomycin / adverse effects
-
Bleomycin / therapeutic use*
-
Drug Therapy, Combination
-
Female
-
Humans
-
Liver Neoplasms / drug therapy
-
Lomustine / adverse effects
-
Lomustine / therapeutic use*
-
Lung Neoplasms / drug therapy
-
Lymphatic Metastasis
-
Male
-
Melanoma / drug therapy*
-
Middle Aged
-
Neoplasm Metastasis
-
Nitrosourea Compounds / therapeutic use*
-
Skin Neoplasms / drug therapy*
-
Vincristine / adverse effects
-
Vincristine / therapeutic use*
Substances
-
Nitrosourea Compounds
-
Bleomycin
-
Vincristine
-
Lomustine